Figures
Abstract
Some of the tryptophan catabolites produced through the kynurenine pathway (KP), and more particularly the excitotoxin quinolinic acid (QA), are likely to play a role in the pathogenesis of Alzheimer's disease (AD). We have previously shown that the KP is over activated in AD brain and that QA accumulates in amyloid plaques and within dystrophic neurons. We hypothesized that QA in pathophysiological concentrations affects tau phosphorylation. Using immunohistochemistry, we found that QA is co-localized with hyperphosphorylated tau (HPT) within cortical neurons in AD brain. We then investigated in vitro the effects of QA at various pathophysiological concentrations on tau phosphorylation in primary cultures of human neurons. Using western blot, we found that QA treatment increased the phosphorylation of tau at serine 199/202, threonine 231 and serine 396/404 in a dose dependent manner. Increased accumulation of phosphorylated tau was also confirmed by immunocytochemistry. This increase in tau phosphorylation was paralleled by a substantial decrease in the total protein phosphatase activity. A substantial decrease in PP2A expression and modest decrease in PP1 expression were observed in neuronal cultures treated with QA. These data clearly demonstrate that QA can induce tau phosphorylation at residues present in the PHF in the AD brain. To induce tau phosphorylation, QA appears to act through NMDA receptor activation similar to other agonists, glutamate and NMDA. The QA effect was abrogated by the NMDA receptor antagonist memantine. Using PCR arrays, we found that QA significantly induces 10 genes in human neurons all known to be associated with AD pathology. Of these 10 genes, 6 belong to pathways involved in tau phosphorylation and 4 of them in neuroprotection. Altogether these results indicate a likely role of QA in the AD pathology through promotion of tau phosphorylation. Understanding the mechanism of the neurotoxic effects of QA is essential in developing novel therapeutic strategies for AD.
Citation: Rahman A, Ting K, Cullen KM, Braidy N, Brew BJ, Guillemin GJ (2009) The Excitotoxin Quinolinic Acid Induces Tau Phosphorylation in Human Neurons. PLoS ONE 4(7): e6344. https://doi.org/10.1371/journal.pone.0006344
Editor: Christophe Egles, Tufts University, United States of America
Received: March 30, 2009; Accepted: June 17, 2009; Published: July 22, 2009
Copyright: © 2009 Rahman et al. This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.
Funding: This work has been supported by research grants from: The University of NSW, The Mason Foundation, Alzheimer Australia and the Rebecca Cooper Foundation. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.
Competing interests: The authors have declared that no competing interests exist.
Introduction
The kynurenine pathway (KP) (Figure 1) is a major route of L-tryptophan catabolism, resulting in the production of nicotinamide adenine dinucleotide (NAD+) and other neuroactive intermediates[1]. Within the CNS, KP metabolites can have either neurotoxic or neuroprotective effects. Among them, quinolinic acid (QA) is perhaps the most important in terms of biological activity. Stone and Perkins were the first to demonstrated QA ability to selectively activate neurons expressing NMDA receptors[2]. QA neurotoxicity was then shown by Schwarcz[3]. QA leads acutely to human neuronal death and chronically to dysfunction by at least five mechanisms[4] and is known to be involved in several major neuroinflammatory diseases[4], [5], [6] including Alzheimer's disease (AD)[7].
A hallmark of AD and related tauopathies, such as frontotemporal dementia, is the formation and accumulation of neurofibrillary tangles (NFTs) within neurons. NFTs are composed of paired helical filaments (PHF)[8], [9] of which the microtubule associated protein tau in an abnormally hyperphosphorylated state, represents the major protein component[10], [11]. The phosphorylation state of tau determines its biological activity[12]. Physiologically, tau promotes the assembly and maintenance of the microtubule structures. Abnormally hyperphosphorylated tau (HPT) has less affinity for binding with microtubules. HPT also sequesters normal tau and other microtubule-associated proteins (MAP1 and MAP2) and causes disassembly of microtubules[13].
We have previously shown that the KP is activated in AD brain, leading to an increase in QA production[14]. We also found that in the hippocampus of AD patients, QA immunoreactivity is detected in cortical microglia, astrocytes and neurons. Of particular interest is the high immunoreactivity of QA in the perimeter of senile plaques and NFTs[15]. Human neurons do not produce QA but they can take it up[16], [17]. The presence of a strong QA immunoreactivity in vacuoles of hippocampal and entorhinal neurons[15] is more likely the consequence of an uptake mechanism rather than synthesis of QA. Neuronal uptake of QA is likely to be part of a scavenging process in which activated microglia and/or infiltrating macrophages release high concentration of QA[16], [17]. In vitro, chronic exposure of rat corticostriatal cultures to nanomolar QA concentrations leads to ultrastructural changes in neurons[18]. Moreover, both low level chronic (350 nM) and high level acute (1 µM) exposures of human primary neurons to QA are neurotoxic[19]. Indeed, chronic exposure of human neurons to QA causes significant structural changes including dendritic beading, microtubular disruption and a decrease in organelles. Altogether, the activation of the KP and the over-production of QA in AD brain, and the co-localization of QA with the histopathological lesions, particularly the QA accumulation in dystrophic neurons with the NFTs led us to hypothesize that QA is directly involved in the hyperphosphorylation of tau.
We found that QA accumulates in neurons and co-localizes with tau in cortical sections from AD patients. In addition, in vitro treatment of human foetal neurons with pathophysiological concentrations of QA significantly increased tau phosphorylation at multiple phosphorylation sites. Our data also show a decrease in the expression and activity of serine/threonine protein phosphatase(s), as the mechanism for tau hyperphosphorylation. We also found that QA induces at least ten neuronal genes, with some of them known to be strongly associated with Alzheimer pathology. This study provides a new insight into the mechanism of QA neurotoxicity and its important role in the pathogenesis of AD. This work has opened a new avenue for research on AD, in particular the application of a novel therapeutic target.
Materials and Methods
Reagents and chemicals
All neuronal cell culture media and additives were from Invitrogen (Mulgrave, VIC, Australia) unless otherwise stated. DAPI and mouse monoclonal antibodies (mAb) for β-actin and all chemicals used for Western blots, immunoprecipitation, Phosphatase (PP) activity and immunoblots (unless otherwise mentioned) were obtained from Sigma-Aldrich Chemical Co. (Sydney, NSW, Australia). IFN-γ was purchased from R&D Systems (Australia), pAb tau from DAKO, mAbs anti-tau 5 from Abcam, tau AT8 and tau AT180 from Pierce Endogen. mAb PHF-1 (developed by Prof Peter Davies, Department of Pathology, Albert Einstein, College of Medicine) and mAb AT270 (Pierce Endogen) were generously provided by Prof Jurgen Goetz (University of Sydney, NSW, Australia). Protein phosphatase antibodies PP1c and PP2Ac were kindly provided by Alistair Sim (University of Newcastle, NSW, Australia). Secondary anti-mouse IgG, anti-rabbit Alexa -conjugated antibodies (594 and 647) and streptavidin-Alexa (594 and 647) were purchased from Molecular Probes (Invitrogen, Eugene, OR, USA). Biotinylated anti-mouse and anti-rabbit antibodies were obtained from Vector Laboratories, Burlingame CA USA). All commercial antibodies were used within the concentration ranges recommended by the manufacturer.
Ethics statement
Human foetal tissue was obtained following informed written consent. This has been approved by the Human Ethics Committees from the University of New South Wales (UNSW Ethic approval HREC 03187). Blocks of human brain tissue were obtained from the National Neural Tissue Resource Centre (NNTRC) and the Australian Brain Bank Network. This study had the approval of the Human Ethics committee of the University of Sydney (10-2005/4/8616).
Cell cultures
Human foetal brains were obtained from 16 to 19 week old foetuses (HREC 03187). Primary cultures of human neurons were prepared as previously described[16]. Briefly, cells were plated in culture flasks coated with Matrigel (diluted 1/20 in Neurobasal medium) and maintained in Neurobasal medium supplemented with 2% (v/v) B-27 supplement, 2 mM Glutamax, 50 mM HEPES, 200 IU/ml penicillin G, 200 µg/ml streptomycin sulphate and 5 mM glucose. Cultures were kept at 37°C at 5% CO2 in a humidified atmosphere. The medium was changed once or twice per week. Neurons were maintained for up to 10 weeks.
Immunocytochemistry for tau
The method has been previously described[16]. Human foetal neurons were grown at a density of 5×106 in Permanox chamber-slides (NUNC) for 2 weeks. Then, cells were fixed with acetone/methanol (vol/vol) for 20 min at –20°C. Cells were then rinsed 3 times with PBS and a gentle membranous permeabilization was performed by incubation with 0.025% Triton X 100 in PBS for 10 min at room temperature. After washing, cells were incubated with 5% normal goat serum (NGS) in PBS for 45 min at room temperature, rinsed twice with PBS and incubated for 1 h at 37°C with selected primary antibody Tau mAbs (Tau 5, AT8 and AT180) diluted in 5% NGS. Cells were then washed with 5% NGS solution and incubated for 1 h at 37°C with the appropriate labelled secondary antibodies (goat anti-mouse IgG or goat anti-rabbit coupled with Alexa 594). Nuclear staining was performed using DAPI at 1 µg/ml for 5 min at room temperature. After several washings with PBS at 37°C, the cover slips were quickly mounted on glass slides with Fluoromount-G, and examined using an Olympus BX60 fluorescence microscope associated with a digital SensiCam. The following three controls were performed for each labelling experiment: 1) isotypic antibody controls for mAbs and serum control for pAbs, 2) incubation with only the secondary labelled antibodies, 3) estimation of auto-fluorescence of unlabelled cells.
Quinolinic acid immunohistochemistry in AD brain tissue
Increased QA expression was confirmed in AD tissue. Brain tissue was acquired through the NSW and Victorian Brain Bank Networks supported by the National Health and Medical Research Council. The study has the approval of the Human Ethics Committees at the University of Sydney. Two age matched controls and 8 AD cases with a range of neuropathological severity were examined. Blocks of tissue were taken from 3–5 mm formalin-fixed coronal slices of the medial temporal lobe, anterior cingulate and superior frontal cortex. On a CO2 Leica microtome, blocks were sectioned at 45 µm into 0.1 M Tris buffer (pH 7.4) containing 0.01% azide. Serial sections were labelled for QA (mAb, developed by Chemicon for our group) and tau (AT8, AT180, Pierce Endogen). Free floating sections were washed three times for 15 minutes each in 50% ethanol then placed in blocking buffer (0.1 M Tris, 1% bovine serum albumin, 0.01% azide, 0.01% TritonX) for 20 minutes, then incubated in 1° antibody for 24 hrs at 4°C. Sections were washed three times for 15 minutes each in 0.1 M Tris and incubated in species-specific biotinylated antibody for 1 hr, washed and placed in streptavidin-Alexa 647 or 594 (Molecular Probes, Invitrogen) diluted 1∶100 in 0.1 M Tris with 0.01% TritonX for 1 hr. For double-immunostaining, the sections were washed for one hour, incubated in blocking buffer, then transferred to the second primary antibody solution. For viewing, sections were mounted on gelatinized glass slides, cover-slipped in gelatine/glycerol and examined with a Zeiss Axioplan microscope. Optical sections were taken through the sections at 2 µm intervals and reconstructed using Zeiss Axiovision software and ImageJ (NIH; Rasband, W.S., ImageJ, U. S. National Institutes of Health, Bethesda, Maryland, USA, http://rsb.info.nih.gov/ij/, 1997–2008).
Preparation of neuronal lysates for Western blots
For Western blots, cells were cultured in Matrigel coated 12-well plates at a density of 1×106 cells per well in supplemented Neurobasal medium supplemented (as described above). Neurons were incubated with various concentrations of QA (ranging from 50 to 1200 nM) for 72 hours. Control cultures were kept in the medium alone. Okadaic acid (100 nM) was used as positive control for tau phosphorylation. In a separate experiment, neurons were cultured with 500 nM each of NMDA receptor agonists (QA, glutamate, NMDA) and antagonists (memantine, AP-5 and MK-801) for 72 hrs. Cells were lysed in 500 µl of RIFA buffer, (50 mM Tris, pH 7.4, 150 mM NaCl, 1% NP-40, 5 mM EDTA, 0.5% sod. deoxycholate, 0.1% SDS, 50 nM NaF, 1 mM sodium vanadate, 2 µg/ml aprotinin, 2 µg/ml pepstatin and 5 µg/ml leupeptin). The cell lysate was centrifuged at 16000 g for 10 minutes. Protein concentration in the supernatant was determined by the modified Lowry method and stored at −20°C until used.
SDS-PAGE and immunoblot analyses
20 µg lysate protein was resolved on 10% SDS-PAGE (NuPAGE 10% from Invitrogen, Carlsbad CA USA) in sample buffer. Protein was transferred onto PVDF membranes; the membranes were blocked with 5% milk in TBS for one hour and incubated with primary antibody overnight at 4°C. The primary antibodies used are described in Table 1. After incubation, the membranes were rinsed several times, washed with TBS-tween three times (10 minutes each), and then two times with TBS only. The membranes were then incubated with the secondary antibody for 4 hours at RT, washed as before and developed either with ECL or Chemidox, (Biorad, Hercules, CA, USA) according to the manufacturer instructions. Blots were quantified using the Quantity One 4.6.1 software from Biorad and ImageJ (NIH; Rasband, W.S., ImageJ, U. S. National Institutes of Health, Bethesda, Maryland, USA, http://rsb.info.nih.gov/ij/, 1997–2008).
Phosphatase activity assay
For phosphatase activity, cells were cultured as described above and lysed in the phosphatase activity buffer (50 mM Tris, pH 7.5, 150 mM NaCl, 1% NP-40, 1 mM PMSF, 1 mM benzamidine, 10 mM beta-mercaptoethanol (βME), 2 µg/ml aprotinin, 2 µg/ml pepstatin and 5 µg/ml leupeptin. Total phosphatase activity was determined using pNPP (10 mM) as a substrate in 50 mM Tris-HCl, pH 7.4, 0.1 mg/ml BSA, 3 mM CaCl2, 1 µM calmodulin and 3 mM MnCl2. The reaction mixture was incubated at 30°C for 30 min and the absorbance measured at 405 nm. PP2A activity was indirectly measured by using 10 nM OA in the phosphatase assay buffer and calculating the OA-inhibited activity.
Immunoprecipitation of PP2A
PP2A was immunoprecipitated according the protocol provided by Upstate, New York. Briefly, 4 µg of anti-PP2A (Clone 1D6) (Upstate, New York) was incubated with 100 µl Protein A Sepharose beads (Amersham/Pharmacia) for 4 hours at 4°C on a rotor. The beads were washed with 750 µl TBS 3 times and 2 times with the phosphates lysis buffer. The beads with absorbed anti-PP2A were incubated with 400 µg lysate protein in a total volume of 500 µl overnight at 4°C. Unbound proteins were separated, and the beads were washed (by a brief pulse in table-top centrifuge) with 750 µl of TBS 3 times. For phosphatase activity, 20 µl beads were pelleted and resuspended in 200 µl of phosphatase assay buffer containing 50 mM Tris-HCl, pH 7.4, 3 mM MnCl2 and 10 mM pNPP. The reaction mixture was incubated at 30°C for 30 min with occasional mixing. At the end of incubation, the beads were centrifuged and the clear supernatant was collected into the wells of a 96-well ELISA plate and the absorbance measured at 405 nm. To measure the amount of immunoprecipated PP2A, 20 µl of beads were boiled in 4× sample buffer and subjected to SDS-PAGE and Western blots as described earlier.
PCR array
RT2 Profiler™ PCR Array kit were obtained from SuperArray Bioscience Corporation (Frederick, MD, USA). The Human Signal Transduction PathwayFinder™ RT2Profiler™ PCR Array profiles the expression of 84 key genes representative of 18 different signal transduction pathways. Using real-time PCR, we analysed the expression of a focused panel of genes related to any of the 18 signal transduction pathways involved in the response of human primary neurons to QA 150 nM for 24 h.
Results
Quinolinic acid is found in neurons and microglia in AD cortex
In order to validate the relevance of QA in the mechanism of tau phosphorylation in the human disease, AD and control tissue were labelled for QA and tau (AT8, AT180). We confirmed that QA is found within cortical neurons in AD and, to a substantially lesser degree, in cortical neurons of elderly controls (Figure 2). QA is present intrasomally in punctate structures resembling vesicles and co-localizes with tau-positive fibrillary structures (see also supplementary Figure S3). QA is also seen throughout the parenchyma and enriched within plaques in vesicular structures within microglial processes.
QA (red; Alexa 647) and tau (AT8; green; Alexa 594) immunolabelling in control and AD cingulate cortex (a–e) and hippocampus (f–g). a) Neuritic plaque in the cingulate cortex of a late-stage AD showing the AT8-positive neurites surrounding by QA-positive cells. The majority of this labelling can be seen in vesicle-like structures within microglial cells, however QA+ neurons in the plaque vicinity are also present (asterix). b) Co-localisation of an intracellular neurofibrillary tangle and QA. This tangle containing neuron is contacted by QA+ non-neuronal cells. See also supplementary figure S3 for additional views through this neuron. c) QA-positive vesicles within a microglia and d) neuron. e) Punctate tau-positivity in a neuron also positive for QA. f) 73-year old neurologically normal control hippocampal CA1 pyramidal cells with very faint immunopositivity for QA. This case had small numbers of entrohinal tangles, but otherwise no other AD-type lesions were detected. In non-AD cases, QA+ neurons rarely occurred outside the hippocampal-entorhinal sector. g) Hippocampus of a mild AD case (Braak stage IV) with QA co-localisation with AT8+ intraneuronal tangles. Scale bars 10 µm a–e; 50 µm f–g.
Quinolinic acid treatment induces tau phosphorylation in cultured human foetal neurons
QA 500 and 1200 nM significantly increased not only the level of total tau (Figure 3A), but also tau phosphorylation at the Tau-8 and Tau-180 epitopes (Figure 3B and C, respectively), as shown by the increase in the staining intensity. Cultures treated with 1200 nM QA had less DAPI-stained neurons and a lower intensity of red staining, compared to control culture and cells treated with 500 nM QA, suggesting that QA 1200 nM is neurotoxic.
Primary cultures of human neurons were immunostained for tau phosphorylation with three different antibodies: Line A, staining of total tau using mAb Tau 5 (Abcam); line B, staining of phosphorylated tau using mAb Tau 180 (Innogenetics); and line C, staining of phosphorylated tau using mAb Tau 8 (Innogenetics). The left column corresponds to untreated neurons, the middle column to QA 500 nM treated cells and the right column to QA 1200 nM treated cells. The histograms represent the semi-quantification of the immunostaining intensity. Intensity has been quantified using ImageJ 10.2. This experiment has been performed in triplicate with primary cultures of neurons prepared from three different brains. Three individual microscopic fields were analysed for each treatment and the SEM for the data was determined to be <5%.
To further elucidate the effect of QA on tau phosphorylation, human foetal neuronal cultures were treated with four different concentrations of QA for 72 hours and Western blot analyses were performed using four different phosphorylation specific antibodies. Details of the experiment are given in the Materials and Methods and in the figure legend. The results are shown in Figure 4. Okadaic acid (100 nM) was used as positive control. At this concentration okadaic acid increased tau phosphorylation with all the four antibodies studied. Phosphorylation of threonine 181 (AT270) was increased by 20%, serine 199/202 (AT8) by 450%, threonine 231(AT180) by 400% and serine 396/404 (PHF-1) by 70% over the control levels by OA. QA increased phosphorylation of serine 199/202 and threonine 231 in a dose dependent manner over the basal level of phosphorylation in the control cultures (Figure 4). The effect on threonine 181 and serine 396/404 was not dose dependent. Phosphorylation of threonine 181 was slightly (20%) increased by the relatively higher concentrations of QA used, whereas, phosphorylation of serine 396/404 was increased substantially by QA at concentrations of 350 nM or higher. Control cultures showed a substantially higher level of phosphorylation of T181, compared to the other sites tested (Figure 4), and both QA and OA resulted in a minimal increase in the phosphorylation of this site over the control level. An interesting observation was the presence of a higher molecular weight band (∼165 kDa) detected with the antibody AT270 (pT181), which may represent aggregated tau (Figure 5).
Primary human foetal neurons were cultured at a density of 1×106 cells per well in a 12-well plate in the absence or presence various concentrations of QA. 100 nM Okadaic acid was used as positive control for tau phosphorylation. After 72 hours, cells were lysed in RIFA buffer. The lysate protein resolved in 10% SDS-PAGE and Western blot performed with the antibodies indicated. Antibodies tested are: A, AT8 (1∶1000 dilution); B, AT180 (1∶1000); C, AT270 (1∶2000); D, PHF-1 (1∶1000). Signal for total tau was determined with the antibody Tau at 1∶1000 dilution. Blots were quantified using the Quantity-One software (Biorad). Signal for phospho tau epitopes was normalized by the signal for total tau and the data expressed as percent of the normalized signal in control cultures. Data presented are the mean (±SD) of five different experiments with neurons from five different brains. Each graph is accompanied with a representative blot in which lane 1 is control; lane 2, 100 nM QA; lane 3, 350 nM QA; lane 4, 500 nM QA; lane 5, 1200 nM QA; lane 6, 100 nM Okadaic acid.
A: Representative blot showing the presence of a high molecular weight (∼165 kDa) band recognized by the PHF-specific antibody AT270 in response to QA treatment. Treatments are the same as shown in Figure 4. B: Quantitative estimation of the high molecular weight tau band normalized for total tau. The data presented are the average (±SD) of four experiments from four different brains and are expressed as the ratio of signal for AT270 to that of signal for total tau.
Quinolinic acid decreases the expression and activity of serine/threonine protein phosphatases in cultured human foetal neurons
In order to investigate if the increased phosphorylation of tau was due to a decrease in the phosphatase activity of neurons, we investigated the effect of QA on phosphatase activity using pNPP as a substrate. We observed an apparent increase in total phosphatase activity at 100 nm QA, but a dose dependent decrease thereafter at higher concentrations used (Figure 6A). Since PP2A is the major phosphatase activity, we indirectly measured PP2A activity in the presence of 10 nM OA, and calculated the OA-inhibited (PP2A) activity. QA inhibited OA-inhibited phosphatase activity in a dose dependent manner (Figure 6B). To confirm these results, we immunoprecipated PP2A from the lysate onto protein A agarose beads and measured the phosphatase activity of immunoprecipitated PP2A towards pNPP. All concentrations of QA tested decreased phosphatase activity by approximately 30%. The decrease was, however, not dose dependent (Figure 6C). To confirm these results, and to investigate if this apparent change in phosphatase activity was due to a change in protein expression, we measured the expression levels of PP1, PP2A, PP2B and PP5 by Western blot analyses in the lysate of neurons treated with various concentrations of QA. The results are shown in Figure 7. As shown in Figure 7A, QA treatment decreased the expression of PP1 in a dose dependent manner. QA at a relatively lower concentration of 400 nM decreased PP1 expression to the same extent as achieved by 100 nM OA. A similar dose-dependent decrease in the expression of PP2A (Figure 7B and 7C) and PP5 (Figure 7E) was also observed with QA acid treatment. PP2B expression on the other hand was increased by all concentrations of QA tested (Figure 7D). Maximum increase (∼200% of control) was observed with 200 nM QA. OA treatment also increased PP2B expression.
Neuronal cultures were treated with the concentrations of QA shown, for 72 hours. Cells were lysed in the phosphatase activity buffer (50 mM Tris, pH 7.5, 150 mM NaCl, 1% NP-40, 1 mM PMSF, 1 mM Benzamidine, 10 mM β-mercaptoethanol (βME), 2 µg/ml aprotinin, 2 µg/ml pepstatin and5 µg/ml leupeptin. A: Total phosphatase activity was determined using pNPP (10 mM) as a substrate in 50 mM Tris-HCl, pH 7.4, 0.1 mg/ml BSA, 3 mM CaCl2, 1 µM calmodulin and 3 mM MnCl2. The reaction mixture was incubated at 30°C for 30 min and the absorbance measured at 405 nm. Data shown are the average (±SD) of three experiments. B: OA-inhibited (PP2A) in the lysate of neurons treated with QA. Total phosphatase activity towards pNPP was determined as above in the presence or absence of 10 nM OA. The difference in the activity lost due the addition of 10 nM OA was calculated as PP2A activity. C: Activity of immunoprecipitated PP2A towards pNPP. PP2A was immunoprecipitated from 400 µg lysate protein with anti-PP2A (clone 1D6). 20 µl of bead were resuspended in 200 µl of phosphatase activity buffer containing 50 mM Tris-HCl, pH 7.4, 3 mM MnCl2 and 10 mM pNPP. The reaction mixture was incubated at 30°C for 30 min with occasional mixing. Beads were removed and the OD of the clear supernatant was measured at 405 nm. Data from three separate experiments are shown as mean (±SD).
20 µg lysate protein (or 20 µl PP2A-IP beads for Figure 7C) was resolved on 10% SDS-PAGE, protein transferred on to PVDF membrane and probed with respective antibodies for each phosphatase. For loading control, the same membranes were stripped and re-probed with anti-actin antibody. For PP2A-IP the band of IgG heavy chain was used as loading control. Graph are mean (±SD) of three experiments (from three separate brains) and are accompanied by a representative blots. Each bar of the quantification graph represents the corresponding band above for each phosphatase.
These results strongly support the hypothesis that the excitotoxin QA induces tau phosphorylation by inhibiting the activity and/or expression of multiple serine/threonine protein phosphatases (PP1, PP2A and PP5). Our data also suggest that the apparent observed increase in total phosphatase activity in the neuronal lysate treated with relatively lower concentrations of QA (up to 200 nM) may be due to an increase in PP2B expression and/or activity.
Quinolinic Acid-induced tau phosphorylation in cultured foetal neurons involves the activation of NMDA receptor
Since QA is an NMDA receptor agonist, we investigated the effect of other NMDA receptor agonists (glutamate and NMDA) on tau phosphorylation and tested whether the NMDA receptor antagonists can abrogate QA-induced tau phosphorylation. The results are shown in Figure 8. NMDA receptor agonists, glutamate and NMDA at equimolar concentrations (500 nM) increased tau phosphorylation at serine 199/202 (AT8) and threonine 231 (AT-180), similar to QA. Phosphorylation of tau at the AT8 site by QA was inhibited by memantine (500 nM) but not by AP-5 or MK-801. The combination of all the three antagonists (cocktail) inhibited tau phosphorylation to some degree but not to the extent of inhibition by memantine alone. Phosphorylation at the AT-180 site was inhibited by memantine and MK-801 but not by AP-5. The antagonist cocktail was less effective in inhibiting phosphorylation of threonine 231 than memantine or MK-801 alone. These results suggest that QA-induced tau phosphorylation involve NMDA receptor activation and inhibiting the NMDA receptors by an antagonist inhibits the effect of QA on tau phosphorylation.
Primary cultures of human neurons were treated with 500 nM each of three NMDA receptor agonists (QA, glutamate and NMDA) and three antagonists (memantine, MK-801 and AP-5). One well (termed as cocktail) was treated with a combination of all the three antagonists (500 nM each). Control wells were cultured in medium alone. Cells were cultured for 24 hours and were then lysed in RIFA buffer. 20 µg of protein lysate was resolved on 10% SDS PAGE, transferred onto PVDF membrane and probed with phosphor-specific antibodies AT8 and AT180 (1∶100 dilution). Antibody Tau (DAKO, 1∶10000) was used for total tau. Quantization data is presented as ratios of AT8 and AT-180 signal to total tau signal and is the average (±SD) of three experiments. A representative blot is for each graph is shown in the insert.
Quinolinic Acid treatment induces the expression of genes that are involved in AD pathology and tau phosphorylation
We investigated the expression of genes related to several signalling pathways in neuronal cultures treated with QA for 24 hours. Of the 84 genes tested, QA induced the expression of 10 genes (Figure 9 and Table 2) by more than two-fold over the control cultures. All these 10 genes are linked with AD pathology and 6 are known to be involved in tau phosphorylation. Details of the over-expressed genes and their reported roles in AD pathology, tau phosphorylation and neuroprotection are given in Table 2.
The 3D histogram shows 84 genes tested in the Pathfinder kit®. Only 10 genes (in red) were significantly increased (expression>2x the control). No genes were significantly decreased.
Discussion
We previously found that QA accumulates in AD brain and interestingly was seen in dystrophic hippocampal neurons [15]. We confirm this here and show co-localization with HPT in cortical and hippocampal neurons. QA is also seen in non-neuronal cells (microglia), which is likely to be the source for neuronal uptake. The present study was designed to assess the potential effect of QA on tau phosphorylation. In accord with our hypothesis, we demonstrated that QA increases tau phosphorylation and so is likely to be a critical factor involved in NFTs formation and subsequent neuronal death. Ultimately, QA accumulation could lead to a worsening of AD neuropathogenesis.
Tau is a phosphoprotein that can be phosphorylated at multiple serine and threonine residues. Hyperphosphorylated tau is assembled into paired helical filaments (PHF) leading to the formation of NFTs[11]. At least thirty serine/threonine phosphorylation sites have been identified in abnormally hyperphosphorylated tau from AD brain[20]. Mechanisms of tau hyperphosphorylation are still not fully understood. Tau hyperphosphorylation results in the disruption and disassembly of the microtubules and subsequently in neuronal death and memory loss[21]. The neuronal disruption of microtubules by hyperphosphorylated tau, which accumulates as PHF in NFTs, is one of the key features of AD[8], [22].
Several neuroinflammatory mediators are able to activate the KP leading to the production of QA by activated microglia and infiltrating macrophages[4]. Microglial activation is known to occur early in transgenic models of tauopathies and immuno-suppression attenuates tau pathology[23], providing a potential corroborating link between microglial products and tangle formation. Interestingly, other excitotoxins such as kainic acid are also able to increase formation of PHF protein[24]. QA is an NMDA receptor agonist and represents a potent endogenous excitotoxin. Increases in QA concentration are known to be associated with several neurodegenerative diseases[4], [7], [25]. We previously reported the presence of QA in close proximity to NFTs and we also observed that QA accumulates in vacuoles within the cytoplasm of dystrophic neurons. We showed here that QA and NFTs are often co-localized in the brain of AD patients[15], [26]. We found that in vitro human primary neurons can take up exogenous QA (see supplementary Figure S1) but can only catabolize a limited amount[16]. This is likely to be due to a rapid saturation of the catabolising enzyme for QA, quinolinate phosphoribosyltransferase (QPRTase) (EC 2.4.2.19) (Figure 1) (see supplementary Figure S2). We demonstrated that neuronal QPRTase activity begins to be saturated at QA concentrations≥300 nM. Neurons can take up and catabolise QA to produce more NAD+[27], which would provide more energy to the cell and improve DNA repair[28]. The excessive accumulation of QA is likely to induce a cytotoxic cascade within neurons[15], [26].
Taken together these observations led us to investigate whether elevated concentrations of QA may contribute to AD neuropathology by leading to tau hyperphosphorylation. We found that in vitro QA treatment of human primary foetal neurons led to a substantial increase of tau phosphorylation at multiple positions. Sites S199/202, T231 and S396/404 are more sensitive to phosphorylation induced by QA treatment. T181 showed a higher degree of phosphorylation in the control cultures and phosphorylation at this site was not substantially increased by QA treatment. However, QA treatment increased the appearance of a high molecular band (∼165 kDa) detected with antibody AT270, which recognizes pT181. This suggests that QA-induced phosphorylation at this site may increase the aggregation of tau. It has been suggested that phosphorylation of tau at S199, S202, T205, T212, S235, S262 and S404 is required for the sequestration of normal tau, whereas further phosphorylation at positions T231 and S396 is needed for self-assembly. Phosphorylation at T181 and T217 are also suggested to be involved in self-assembly[29]. Whether other serine or threonine residues that are usually phosphorylated in ADP-tau are also phosphorylated by QA treatment remains to be investigated.
The alternative splicing of the tau gene produces six isoforms of tau in adult brain. The six isoforms of tau differ from each other by the presence or absence of one or two inserts in the N-terminal part and by the presence of either three or four repeats in the C-terminal region. Whereas all six isoforms are seen in adult brain, only the shortest isoform of tau is expressed in foetal brain [20]. Although we tested the effect of QA on foetal tau phosphorylation, our results can be extrapolated to adult tau for two reasons. Firstly, about one third of total tau in adult brain is the shortest (foetal) isoform (0N/3R)[20]; and secondly, most of the phosphorylation sites in PHF-tau are also phosphorylated in foetal brain tau[30], [31], [32]. In the AD brain, tau can be hyperphosphorylated by either an increase in the activities of one or more serine/threonine kinases or reduced activity of a phosphoseryl/phosphothreonyl protein phosphatase(s). The role of the kinases in tau hyperphosphorylation has been well studied but increase in activity of any one of these kinases has never been reproducibly shown in AD brain. Phosphoseryl/phosphothreonyl protein phosphatases are among the major regulators of the phosphorylation of tau[33], [34], [35]. Impairment of protein phosphatases not only directly affects the dephosphorylation of tau but may also up-regulate the activity of some protein kinases, which are phosphorylation dependent[35], [36], [37],[38],[39],[40].
The major serine/threonine phosphatases in the brain are PP1, PP2A and PP2B[41], [42], [43], [44]. Although quantitatively PP2B is the most abundantly expressed in the brain, it represents, due to specific activity, a small proportion of total brain phosphatases activity; PP1 and PP2A together account for over 90% of the total mammalian brain protein phosphatase activity, and any alteration in the activity of these two phosphatases may significantly affect the phosphorylation state of tau. A decrease of about 20% in the activities of PP1 and PP2A has been reported in AD brain[45], [46]. The observed increase in QA-induced phosphorylation of tau could be due to a decrease in the expression or activity of the major tau phosphatases. We measured total and OA-inhibited (PP2A) phosphatase activity in QA-treated neuronal lysate. We also measured the activity of immunoprecipitated PP2A from QA-treated neuronal lysate. We observed a biphasic effect on total phosphatase activity, using pNPP as substrate. The activity was increased at 100 nM QA but higher concentrations decreased the activity in a dose-dependent manner. However, PP2A activity (measured indirectly as OA-inhibited phosphatase activity and directly by immunoprecipitating PP2A and measuring its activity) was markedly decreased in a dose dependent manner.
We measured the expression level of PP1, PP2A, PP2B and PP5. QA treatment decreased the expression of PP1, PP2A and PP5 in a dose dependent manner. These data suggest that the observed reduction in phosphatase activity and subsequent tau phosphorylation is due to a decrease in the expression of the major tau phosphatases. The expression of PP2B, on the other hand, was markedly increased. The observed increase in total phosphatase activity with lower concentrations of QA (100–200 nM) could be due to an increase in PP2B activity. Liu et al. [44] have reported that PP2A, PP1, PP5 and PP2B account for ∼71%, ∼11%, ∼10% and ∼7%, respectively, of the total tau phosphatase activity of human brain. Increased expression of PP2B could be a compensatory mechanism for the substantial decrease in PP2A and PP1 activities. Our results are in accordance with the published literature reporting the increased expression of PP2B in AD brain, which is characterized by tau hyperphosphorylation. Up-regulation of PP2B expression in the pyramidal neurons of hippocampus in AD brain has been previously reported[47]. An increase in the catalytic cleavage and subsequent increase in the activity of PP2B in AD brain has also been reported[44].
Since QA is an NMDA receptor agonist, we investigated whether other agonists had a similar effect on tau phosphorylation. Both glutamate and NMDA increased tau phosphorylation at sites similar to QA. An increase in tau phosphorylation by glutamate has been reported previously[48]. We also studied the effects of various NMDA receptor antagonists on QA-induced tau phosphorylation. Of the antagonists studied, only memantine almost completely reversed QA-induced tau phosphorylation. MK-801 inhibited tau phosphorylation at AT-180 site but not at AT8 site, whereas, AP-5 had no effect at either site. Inhibition of okadaic acid-induced tau phosphorylation to the control level by memantine but not by other antagonists (5,7-dichlorokynurenic acid (DK) or with D(-)-2-amino-5-phosphonopentanoic acid (AP) in organotypic cultures of rat hippocampal slices has been reported by Li et al.52 and this observation is consistent with our findings. In this study memantine also reversed the OA-induced decrease in PP-2A activity, increase in calcium, calmodulin-dependent protein kinase II (CaMKII) and cyclin AMP-dependent PKA activities, the decrease and aggregation of MAP-2 and the phosphorylation and aggregation of neurofilament heavy/medium (NF-H/M) subunits and inhibited the neurodegeneration associated with these changes. Memantine is a low to moderate affinity non-competitive NMDA receptor channel blocker that leads to functional improvement and reduces care dependence in moderate to severe AD patients[49], [50]. The NMDA receptor has been reported to be associated with PP-2A and stimulation of this receptor can lead to the dissociation of PP-2A from the complex and the reduction of PP-2A activity in cultured cells[51]. It has been suggested that, in addition to its activity as an NMDA receptor antagonist, the effects of memantine might involve modulation of PP-2A signalling, a property not shared by the other NMDA receptor antagonists[48].
Finally, we used PCR array to determine which of the genes associated with tau phosphorylation may be switched on by QA. We found that QA at the sub-physiological concentrations found in amyloid plaques[26] was able to activate 10 genes in primary human neurons (Fig. 10; table 2). Six of these genes e.g. CDK5, MYC, WNT1, IL1α, iNOS and BRCA1 are associated with intracellular pathways known to play a role in tau phosphorylation (Table 2). The other genes WISP1, LEP, C/EBPB and CSF2 are known to be associated with neuroprotective mechanisms and are logically activated in response to QA.
In conclusion, we showed in this study that QA over-production by activated microglia/macrophages and consequent accumulation in AD brain is likely to be involved in two mechanisms 1) promotion of tau pathology by inducing tau hyperphosphorylation and 2) direct excitotoxicity (Figure 10). We propose that a decrease in major tau phosphatases (PP2A, PP1 and PP5) is a mechanism for this increased in tau phosphorylation in neurons exposed to QA at pathophysiological concentrations. This study has identified a new mechanism involved in AD neurodegeneration and may open a new therapeutic avenue for treatment of AD.
Supporting Information
Figure S1.
QA uptake by human neurons in vitro. These data demonstrate that QUIN is taken up by human primary neurons in vitro.
https://doi.org/10.1371/journal.pone.0006344.s001
(0.29 MB PDF)
Figure S2.
Determination of QPRTase activity in human neuron. We developed a new method to quantify QPRTase activity and we found that neuronal QPRTase activity starts to be saturated at concentrations above 300 nM.
https://doi.org/10.1371/journal.pone.0006344.s002
(0.15 MB PDF)
Figure S3.
Intracellular co-localization of neurofibrillary tangle and QA in a human neuron. Serial optical sections were taken through the neuron at 2 µm intervals. QA (red; Alexa 647) and tau (AT8; green; Alexa 594).
https://doi.org/10.1371/journal.pone.0006344.s003
(0.60 MB PDF)
Acknowledgments
We thank Prof Jürgen Goetz (University of Sydney) and Prof Alistair Sims (University of Newcastle) for the aliquots of tau antibodies. We thank Rachel Evans (Centre for Immunology) for her help with the western blot. We thank the National Neural Tissue Resource Centre (NNTRC), Australian Brain Bank Network, supported by the National Health and Medical Research council of Australia and the Department of Pathology, the University of Melbourne.
Author Contributions
Conceived and designed the experiments: AR GJG. Performed the experiments: AR KKT KMC NB GJG. Analyzed the data: AR GJG. Contributed reagents/materials/analysis tools: BJB GJG. Wrote the paper: AR GJG. Helped with the writing and editing of the paper: KMC NB BJB.
References
- 1. Stone TW (1993) Neuropharmacology of quinolinic and kynurenic acids. Pharmacol Rev 45: 309–379.
- 2. Stone TW, Perkins MN (1981) Quinolinic acid: a potent endogenous excitant at amino acid receptors in CNS. Eur J Pharmacol 72: 411–412.
- 3. Schwarcz R, Whetsell WO Jr, Mangano RM (1983) Quinolinic acid: an endogenous metabolite that produces axon-sparing lesions in rat brain. Science 219: 316–318.
- 4. Guillemin GJ, Kerr SJ, Brew BJ (2005) Involvement of quinolinic acid in AIDS dementia complex. Neurotox Res 7: 103–123.
- 5. Heyes MP, Saito K, Crowley JS, Davis LE, Demitrack MA, et al. (1992) Quinolinic acid and kynurenine pathway metabolism in inflammatory and non-inflammatory neurological disease. Brain 115(Pt 5): 1249–1273.
- 6. Stone TW (2001) Endogenous neurotoxins from tryptophan. Toxicon 39: 61–73.
- 7. Guillemin GJ, Williams KR, Smith DG, Smythe GA, Croitoru-Lamoury J, et al. (2003) Quinolinic acid in the pathogenesis of Alzheimer's disease. Adv Exp Med Biol 527: 167–176.
- 8. Tomlinson BE, Blessed G, Roth M (1970) Observations on the brains of demented old people. J Neurol Sci 11: 205–242.
- 9. Tolnay M, Probst A (1999) REVIEW: tau protein pathology in Alzheimer's disease and related disorders. Neuropathol Appl Neurobiol 25: 171–187.
- 10. Grundke-Iqbal I, Iqbal K, Tung YC, Wisniewski HM (1984) Alzheimer paired helical filaments: immunochemical identification of polypeptides. Acta Neuropathol (Berl) 62: 259–267.
- 11. Grundke-Iqbal I, Iqbal K, Tung YC, Quinlan M, Wisniewski HM, et al. (1986) Abnormal phosphorylation of the microtubule-associated protein tau (tau) in Alzheimer cytoskeletal pathology. Proc Natl Acad Sci U S A 83: 4913–4917.
- 12. Lindwall G, Cole RD (1984) Phosphorylation affects the ability of tau protein to promote microtubule assembly. J Biol Chem 259: 5301–5305.
- 13. Alonso AC, Grundke-Iqbal I, Iqbal K (1996) Alzheimer's disease hyperphosphorylated tau sequesters normal tau into tangles of filaments and disassembles microtubules. Nat Med 2: 783–787.
- 14. Guillemin GJ, Brew BJ (2002) Implications of the kynurenine pathway and quinolinic acid in Alzheimer's disease. Redox Rep 7: 199–206.
- 15. Guillemin GJ, Brew BJ, Noonan CE, Takikawa O, Cullen KM (2005) Indoleamine 2,3 dioxygenase and quinolinic acid immunoreactivity in Alzheimer's disease hippocampus. Neuropathol Appl Neurobiol 31: 395–404.
- 16. Guillemin GJ, Smythe G, Takikawa O, Brew BJ (2005) Expression of indoleamine 2,3-dioxygenase and production of quinolinic acid by human microglia, astrocytes, and neurons. Glia 49: 15–23.
- 17. Guillemin GJ, Cullen KM, Lim CK, Smythe GA, Garner B, et al. (2007) Characterization of the Kynurenine Pathway in Human Neurons. J Neurosci 27: 12884–12892.
- 18. Whetsell WO Jr, Schwarcz R (1989) Prolonged exposure to submicromolar concentrations of quinolinic acid causes excitotoxic damage in organotypic cultures of rat corticostriatal system. Neurosci Lett 97: 271–275.
- 19. Kerr SJ, Armati PJ, Brew BJ (1995) Neurocytotoxity of quinolinic acid in human brain cultures. J Neurovirol 1: 375–380.
- 20. Gong CX, Liu F, Grundke-Iqbal I, Iqbal K (2005) Post-translational modifications of tau protein in Alzheimer's disease. J Neural Transm 112: 813–838.
- 21. Kopke E, Tung YC, Shaikh S, Alonso AC, Iqbal K, et al. (1993) Microtubule-associated protein tau. Abnormal phosphorylation of a non-paired helical filament pool in Alzheimer disease. J Biol Chem 268: 24374–24384.
- 22. Arriagada PV, Marzloff K, Hyman BT (1992) Distribution of Alzheimer-type pathologic changes in nondemented elderly individuals matches the pattern in Alzheimer's disease. Neurology 42: 1681–1688.
- 23. Yoshiyama Y, Higuchi M, Zhang B, Huang SM, Iwata N, et al. (2007) Synapse loss and microglial activation precede tangles in a P301S tauopathy mouse model. Neuron 53: 337–351.
- 24. Hernandez-Ortega K, Ferrera P, Arias C (2007) Sequential expression of cell-cycle regulators and Alzheimer's disease-related proteins in entorhinal cortex after hippocampal excitotoxic damage. J Neurosci Res 85: 1744–1751.
- 25. Guillemin G, Meininger V, Brew B (2006) Implications for the kynurenine pathway and quinolinic acid in amyotrophic lateral sclerosis. Neurodegenerative diseases 2: 166–176.
- 26. Guillemin GJ, Brew BJ, Noonan CE, Knight TG, Smythe GA, et al. Takai K, editor. (2007) Mass spectrometric detection of quinolinic acid in microdissected Alzheimer's disease plaques. International Congress Series 404–408.
- 27. Braidy N, Grant R, Brew BJ, Adams S, Jayasena T, et al. (2009) Effects of Kynurenine Pathway Metabolites on Intracellular NAD+ synthesis and Cell Death in Human Primary Astrocytes and Neurons. Int J Trypto Res 1:
- 28. Braidy N, Guillemin G, Grant R (2008) Promotion of Cellular NAD+ Anabolism: Therapeutic Potential for Oxidative Stress in Ageing and Alzheimer's Disease. Neurotox Res 13: 1–12.
- 29. Alonso Adel C, Mederlyova A, Novak M, Grundke-Iqbal I, Iqbal K (2004) Promotion of hyperphosphorylation by frontotemporal dementia tau mutations. J Biol Chem 279: 34873–34881.
- 30. Bramblett GT, Goedert M, Jakes R, Merrick SE, Trojanowski JQ, et al. (1993) Abnormal tau phosphorylation at Ser396 in Alzheimer's disease recapitulates development and contributes to reduced microtubule binding. Neuron 10: 1089–1099.
- 31. Goedert M, Jakes R, Crowther RA, Six J, Lubke U, et al. (1993) The abnormal phosphorylation of tau protein at Ser-202 in Alzheimer disease recapitulates phosphorylation during development. Proc Natl Acad Sci U S A 90: 5066–5070.
- 32. Watanabe A, Hasegawa M, Suzuki M, Takio K, Morishima-Kawashima M, et al. (1993) In vivo phosphorylation sites in fetal and adult rat tau. J Biol Chem 268: 25712–25717.
- 33. Gong CX, Lidsky T, Wegiel J, Zuck L, Grundke-Iqbal I, et al. (2000) Phosphorylation of microtubule-associated protein tau is regulated by protein phosphatase 2A in mammalian brain. Implications for neurofibrillary degeneration in Alzheimer's disease. J Biol Chem 275: 5535–5544.
- 34. Bennecib M, Gong CX, Grundke-Iqbal I, Iqbal K (2000) Role of protein phosphatase-2A and -1 in the regulation of GSK-3, cdk5 and cdc2 and the phosphorylation of tau in rat forebrain. FEBS Lett 485: 87–93.
- 35. Bennecib M, Gong CX, Grundke-Iqbal I, Iqbal K (2001) Inhibition of PP-2A upregulates CaMKII in rat forebrain and induces hyperphosphorylation of tau at Ser 262/356. FEBS Lett 490: 15–22.
- 36. Easom RA, Tarpley JL, Filler NR, Bhatt H (1998) Dephosphorylation and deactivation of Ca2+/calmodulin-dependent protein kinase II in betaTC3-cells is mediated by Mg2+- and okadaic-acid-sensitive protein phosphatases. Biochem J 329(Pt 2): 283–288.
- 37. Tanaka T, Zhong J, Iqbal K, Trenkner E, Grundke-Iqbal I (1998) The regulation of phosphorylation of tau in SY5Y neuroblastoma cells: the role of protein phosphatases. FEBS Lett 426: 248–254.
- 38. Kins S, Kurosinski P, Nitsch RM, Gotz J (2003) Activation of the ERK and JNK signaling pathways caused by neuron-specific inhibition of PP2A in transgenic mice. Am J Pathol 163: 833–843.
- 39. Pei JJ, Gong CX, An WL, Winblad B, Cowburn RF, et al. (2003) Okadaic-acid-induced inhibition of protein phosphatase 2A produces activation of mitogen-activated protein kinases ERK1/2, MEK1/2, and p70 S6, similar to that in Alzheimer's disease. Am J Pathol 163: 845–858.
- 40. Zhao WQ, Feng C, Alkon DL (2003) Impairment of phosphatase 2A contributes to the prolonged MAP kinase phosphorylation in Alzheimer's disease fibroblasts. Neurobiol Dis 14: 458–469.
- 41. Gong CX, Grundke-Iqbal I, Damuni Z, Iqbal K (1994) Dephosphorylation of microtubule-associated protein tau by protein phosphatase-1 and -2C and its implication in Alzheimer disease. FEBS Lett 341: 94–98.
- 42. Gong CX, Grundke-Iqbal I, Iqbal K (1994) Dephosphorylation of Alzheimer's disease abnormally phosphorylated tau by protein phosphatase-2A. Neuroscience 61: 765–772.
- 43. Gong CX, Singh TJ, Grundke-Iqbal I, Iqbal K (1994) Alzheimer's disease abnormally phosphorylated tau is dephosphorylated by protein phosphatase-2B (calcineurin). J Neurochem 62: 803–806.
- 44. Liu F, Grundke-Iqbal I, Iqbal K, Gong CX (2005) Contributions of protein phosphatases PP1, PP2A, PP2B and PP5 to the regulation of tau phosphorylation. Eur J Neurosci 22: 1942–1950.
- 45. Gong CX, Shaikh S, Wang JZ, Zaidi T, Grundke-Iqbal I, et al. (1995) Phosphatase activity toward abnormally phosphorylated tau: decrease in Alzheimer disease brain. J Neurochem 65: 732–738.
- 46. Gong CX, Singh TJ, Grundke-Iqbal I, Iqbal K (1993) Phosphoprotein phosphatase activities in Alzheimer disease brain. J Neurochem 61: 921–927.
- 47. Hata R, Masumura M, Akatsu H, Li F, Fujita H, et al. (2001) Up-regulation of calcineurin Abeta mRNA in the Alzheimer's disease brain: assessment by cDNA microarray. Biochem Biophys Res Commun 284: 310–316.
- 48. Li L, Sengupta A, Haque N, Grundke-Iqbal I, Iqbal K (2004) Memantine inhibits and reverses the Alzheimer type abnormal hyperphosphorylation of tau and associated neurodegeneration. FEBS Lett 566: 261–269.
- 49. Winblad B, Poritis N (1999) Memantine in severe dementia: results of the 9M-Best Study (Benefit and efficacy in severely demented patients during treatment with memantine). Int J Geriatr Psychiatry 14: 135–146.
- 50. Reisberg B, Doody R, Stoffler A, Schmitt F, Ferris S, et al. (2003) Memantine in moderate-to-severe Alzheimer's disease. N Engl J Med 348: 1333–1341.
- 51. Chan SF, Sucher NJ (2001) An NMDA receptor signaling complex with protein phosphatase 2A. J Neurosci 21: 7985–7992.
- 52. Evans TA, Raina AK, Delacourte A, Aprelikova O, Lee HG, et al. (2007) BRCA1 may modulate neuronal cell cycle re-entry in Alzheimer disease. Int J Med Sci 4: 140–145.
- 53. McShea A, Lee HG, Petersen RB, Casadesus G, Vincent I, et al. (2007) Neuronal cell cycle re-entry mediates Alzheimer disease-type changes. Biochim Biophys Acta 1772: 467–472.
- 54. Ferrer I, Blanco R, Carmona M, Puig B (2001) Phosphorylated c-MYC expression in Alzheimer disease, Pick's disease, progressive supranuclear palsy and corticobasal degeneration. Neuropathol Appl Neurobiol 27: 343–351.
- 55. Mudher A, Chapman S, Richardson J, Asuni A, Gibb G, et al. (2001) Dishevelled regulates the metabolism of amyloid precursor protein via protein kinase C/mitogen-activated protein kinase and c-Jun terminal kinase. J Neurosci 21: 4987–4995.
- 56. De Ferrari GV, Chacon MA, Barria MI, Garrido JL, Godoy JA, et al. (2003) Activation of Wnt signaling rescues neurodegeneration and behavioral impairments induced by beta-amyloid fibrils. Mol Psychiatry 8: 195–208.
- 57. Scali C, Caraci F, Gianfriddo M, Diodato E, Roncarati R, et al. (2006) Inhibition of Wnt signaling, modulation of Tau phosphorylation and induction of neuronal cell death by DKK1. Neurobiol Dis 24: 254–265.
- 58. Sengupta A, Novak M, Grundke-Iqbal I, Iqbal K (2006) Regulation of phosphorylation of tau by cyclin-dependent kinase 5 and glycogen synthase kinase-3 at substrate level. FEBS Lett 580: 5925–5933.
- 59. Tanji K, Mori F, Imaizumi T, Yoshida H, Satoh K, et al. (2003) Interleukin-1 induces tau phosphorylation and morphological changes in cultured human astrocytes. Neuroreport 14: 413–417.
- 60. Saez TE, Pehar M, Vargas M, Barbeito L, Maccioni RB (2004) Astrocytic nitric oxide triggers tau hyperphosphorylation in hippocampal neurons. In Vivo 18: 275–280.
- 61. Lee SC, Zhao ML, Hirano A, Dickson DW (1999) Inducible nitric oxide synthase immunoreactivity in the Alzheimer disease hippocampus: association with Hirano bodies, neurofibrillary tangles, and senile plaques. J Neuropathol Exp Neurol 58: 1163–1169.
- 62. Li R, Strohmeyer R, Liang Z, Lue LF, Rogers J (2004) CCAAT/enhancer binding protein delta (C/EBPdelta) expression and elevation in Alzheimer's disease. Neurobiol Aging 25: 991–999.
- 63. Marshall J, Dolan BM, Garcia EP, Sathe S, Tang X, et al. (2003) Calcium channel and NMDA receptor activities differentially regulate nuclear C/EBPbeta levels to control neuronal survival. Neuron 39: 625–639.
- 64. Maurer MH, Schabitz WR, Schneider A (2008) Old friends in new constellations–the hematopoetic growth factors G-CSF, GM-CSF, and EPO for the treatment of neurological diseases. Curr Med Chem 15: 1407–1411.
- 65. Tarkowski E, Wallin A, Regland B, Blennow K, Tarkowski A (2001) Local and systemic GM-CSF increase in Alzheimer's disease and vascular dementia. Acta Neurol Scand 103: 166–174.
- 66. Dicou E, Attoub S, Gressens P (2001) Neuroprotective effects of leptin in vivo and in vitro. Neuroreport 12: 3947–3951.